372 related articles for article (PubMed ID: 35282535)
1. Advancements in the Treatment of Triple-Negative Breast Cancer: A Narrative Review of the Literature.
Landry I; Sumbly V; Vest M
Cureus; 2022 Feb; 14(2):e21970. PubMed ID: 35282535
[TBL] [Abstract][Full Text] [Related]
2. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review.
Li CH; Karantza V; Aktan G; Lala M
Breast Cancer Res; 2019 Dec; 21(1):143. PubMed ID: 31842957
[TBL] [Abstract][Full Text] [Related]
3. Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies.
Gupta GK; Collier AL; Lee D; Hoefer RA; Zheleva V; Siewertsz van Reesema LL; Tang-Tan AM; Guye ML; Chang DZ; Winston JS; Samli B; Jansen RJ; Petricoin EF; Goetz MP; Bear HD; Tang AH
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32846967
[TBL] [Abstract][Full Text] [Related]
4. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
5. Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates.
Nagayama A; Vidula N; Bardia A
Oncology (Williston Park); 2021 May; 35(5):249-254. PubMed ID: 33983696
[TBL] [Abstract][Full Text] [Related]
6. Early-stage triple negative breast cancer: the therapeutic role of immunotherapy and the prognostic value of pathological complete response.
De Santis P; Perrone M; Guarini C; Santoro AN; Laface C; Carrozzo D; Oliva GR; Fedele P
Explor Target Antitumor Ther; 2024; 5(1):232-250. PubMed ID: 38464390
[TBL] [Abstract][Full Text] [Related]
7. The pathological and clinical landscape of refractory metastatic triple negative breast cancer: a narrative review.
Jiang MP; Huang X; Yin YM; Tang JH
Ann Transl Med; 2022 Aug; 10(16):907. PubMed ID: 36111045
[TBL] [Abstract][Full Text] [Related]
8. [Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates].
Dalenc F; Sarradin V; Nicolaï V; Franchet C; Ung M
Bull Cancer; 2021 Jan; 108(1):67-79. PubMed ID: 33422340
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
Isaacs J; Anders C; McArthur H; Force J
Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
[TBL] [Abstract][Full Text] [Related]
10. New Therapeutic Strategies for Triple-Negative Breast Cancer.
Székely B; Silber AL; Pusztai L
Oncology (Williston Park); 2017 Feb; 31(2):130-7. PubMed ID: 28205193
[TBL] [Abstract][Full Text] [Related]
11. BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-Making.
Pavese F; Capoluongo ED; Muratore M; Minucci A; Santonocito C; Fuso P; Concolino P; Di Stasio E; Carbognin L; Tiberi G; Garganese G; Corrado G; Di Leone A; Generali D; Fragomeni SM; D'Angelo T; Franceschini G; Masetti R; Fabi A; Mulè A; Santoro A; Belli P; Tortora G; Scambia G; Paris I
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230495
[TBL] [Abstract][Full Text] [Related]
12. Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab.
Molinero L; Li Y; Chang CW; Maund S; Berg M; Harrison J; Fassò M; O'Hear C; Hegde P; Emens LA
J Immunother Cancer; 2019 Oct; 7(1):274. PubMed ID: 31647026
[TBL] [Abstract][Full Text] [Related]
13. OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancer.
Tolaney SM; DeMichele A; Takano T; Rugo HS; Perou C; Lynce F; Parsons HA; Santa-Maria CA; Rocque GB; Yao W; Sun SW; Mocci S; Partridge AH; Carey LA
Future Oncol; 2024 Jun; ():1-21. PubMed ID: 38922307
[TBL] [Abstract][Full Text] [Related]
14. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
[TBL] [Abstract][Full Text] [Related]
15. Immune-Based Therapy in Triple-Negative Breast Cancer: From Molecular Biology to Clinical Practice.
Carlino F; Diana A; Piccolo A; Ventriglia A; Bruno V; De Santo I; Letizia O; De Vita F; Daniele B; Ciardiello F; Orditura M
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565233
[TBL] [Abstract][Full Text] [Related]
16. Research advances and new challenges in overcoming triple-negative breast cancer.
Zong Y; Pegram M
Cancer Drug Resist; 2021; 4(3):517-542. PubMed ID: 34888495
[TBL] [Abstract][Full Text] [Related]
17. Tumor Mutational Burden and
Barroso-Sousa R; Keenan TE; Pernas S; Exman P; Jain E; Garrido-Castro AC; Hughes M; Bychkovsky B; Umeton R; Files JL; Lindeman NI; MacConaill LE; Hodi FS; Krop IE; Dillon D; Winer EP; Wagle N; Lin NU; Mittendorf EA; Van Allen EM; Tolaney SM
Clin Cancer Res; 2020 Jun; 26(11):2565-2572. PubMed ID: 32019858
[TBL] [Abstract][Full Text] [Related]
18. Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights.
Lucas MW; Kelly CM
Cancer Manag Res; 2022; 14():2493-2506. PubMed ID: 35999966
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: a systematic review and meta-analysis.
Caramelo O; Silva C; Caramelo F; Frutuoso C; Pinto L; Almeida-Santos T
Hered Cancer Clin Pract; 2022 Sep; 20(1):34. PubMed ID: 36085046
[TBL] [Abstract][Full Text] [Related]
20. Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC).
Lee J
J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36836059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
